Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
出版年份 2012 全文链接
标题
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
作者
关键词
-
出版物
JOURNAL OF LIPID RESEARCH
Volume 53, Issue 9, Pages 1755-1766
出版商
American Society for Biochemistry & Molecular Biology (ASBMB)
发表日期
2012-05-02
DOI
10.1194/jlr.r024075
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial
- (2012) Thomas F. Lüscher et al. EUROPEAN HEART JOURNAL
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
- (2012) Benjamin F Voight et al. LANCET
- Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein
- (2012) Lei Zhang et al. Nature Chemical Biology
- Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein
- (2011) Michael-Friedrich Boettcher et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
- (2011) Philip J. Barter et al. CIRCULATION
- Torcetrapib impairs endothelial function in hypertension
- (2011) Branko Simic et al. EUROPEAN HEART JOURNAL
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol
- (2011) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure
- (2011) Guoqing Cao et al. JOURNAL OF LIPID RESEARCH
- Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters
- (2011) Jose Castro-Perez et al. JOURNAL OF LIPID RESEARCH
- Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
- (2011) Ronald M. Krauss et al. JOURNAL OF LIPID RESEARCH
- Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
- (2011) Zahi A Fayad et al. LANCET
- Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
- (2010) Laurent Yvan-Charvet et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effects of High-Density Lipoproteins on Pancreatic β-Cell Insulin Secretion
- (2010) Michelle A. Fryirs et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels
- (2010) Roger G Clerc et al. JOURNAL OF HYPERTENSION
- Biochemical characterization of cholesteryl ester transfer protein inhibitors
- (2010) Mollie Ranalletta et al. JOURNAL OF LIPID RESEARCH
- Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
- (2010) Eric J. Niesor et al. JOURNAL OF LIPID RESEARCH
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
- (2009) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
- (2009) Philip Barter AMERICAN JOURNAL OF CARDIOLOGY
- Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats
- (2009) ESG Stroes et al. BRITISH JOURNAL OF PHARMACOLOGY
- High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus
- (2009) Brian G. Drew et al. CIRCULATION
- Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms
- (2009) Reecha Sofat et al. CIRCULATION
- Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction
- (2009) Paul M. Ridker et al. Circulation-Cardiovascular Genetics
- The hypertension peril: Lessons from CETP inhibitors
- (2009) Matthias Hermann et al. CURRENT HYPERTENSION REPORTS
- Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition
- (2009) Xiao Hu et al. ENDOCRINOLOGY
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- (2009) The Emerging Risk Factors Collaboration* JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
- (2008) M J Forrest et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis
- (2008) Stephen J. Nicholls et al. CIRCULATION
- Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
- (2008) Alexander Thompson JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The metabolism and anti-atherogenic properties of HDL
- (2008) Kerry-Anne Rye et al. JOURNAL OF LIPID RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More